An Extension of the TG1101-RMS201 Trial
Public ClinicalTrials.gov record NCT03381170. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Study identification
- NCT ID
- NCT03381170
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 1, 2017 (Actual)
- Primary completion
- Nov 11, 2022 (Actual)
- Completion
- Nov 11, 2022 (Actual)
- Last update posted
- Dec 21, 2022
2017 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | Pasadena | California | 91105 | — |
| TG Therapeutics Investigational Trial Site | Aurora | Colorado | 80045 | — |
| TG Therapeutics Investigational Trial Site | Lexington | Kentucky | 40513 | — |
| TG Therapeutics Investigational Trial Site | Columbus | Ohio | 43210 | — |
| TG Therapeutics Investigational Trial Site | Westerville | Ohio | 43081 | — |
| TG Therapeutics Investigational Trial Site | Knoxville | Tennessee | 37922 | — |
| TG Therapeutics Investigational Trial Site | Round Rock | Texas | 78681 | — |
| TG Therapeutics Investigational Trial Site | San Antonio | Texas | 78258 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03381170, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2022 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03381170 live on ClinicalTrials.gov.